1. Improving Stroke Prevention in Patients With Atrial Fibrillation

2. Acknowledgement

3. Disclosures

4. Disclosures (cont.) This presentation will not include any non-FDA approved or investigational uses of products or medical devices.

5. Learning Objectives

6. Atrial Fibrillation (AF): Incidence and Consequences

7. Projected Number of Persons With AF in the US: 2000 to 2050

8. AF and Stroke

9. Greater Risk of Death and Recurrence With AF Strokes

10. Disability vs Age Group in Those With Acute Ischemic Stroke (AIS) vs AF-AIS

11. Anticoagulation: Assessing Benefits and Risks

12. Question

13. Case 1

14. CHADS 2 Index: A Validated Classification Scheme/Tool for Stroke Risk

16. Weakness of CHADS 2

17. The CHA 2 DS 2 -VASc Index

18. CHA 2 DS 2 -VASc vs CHADS 2 : Which to Use?

19. Case 2

20. ACC/AHA/ESC Guidelines

21. Risk Stratification and Anticoagulation

22. Underuse of Anticoagulants in AF

23. Barriers to Anticoagulant Use

24. Barriers to Anticoagulation?

25. Bleeding Risk

26. Bleeding Risk: The Reality

27. Anticoagulation in Patients at Risk of Falls: “Physicians’ Fears Are Often Unfounded”

28. Assessing Bleeding Risk: HAS-BLED

29. Reducing Bleeding Risk

30. Anticoagulation Decision Support Worksheet

31. Anticoagulation Decision Support Worksheet (cont.)

32. The Patient: Decision Making and Education

33. Patient Preferences

34. Patient vs Physician Perspectives on Anticoagulation

35. Explaining Risk to Patients: Numerous Tools Available

36. Patient Knowledge About Warfarin

37. Patient Adherence to Warfarin

38. Risk Factors for Warfarin Nonadherence

39. Improving Patient Adherence to Anticoagulants

40. Which Antithrombotic Therapy?

41. Generic/Trade Name Guide for Drugs Mentioned in Presentation

42. Features of Available Anticoagulants

43. Warfarin and Novel Anticoagulant Mechanisms of Action

44. Choosing an Anticoagulant

45. Question Check

46. Clopidogrel and/or Aspirin?

47. ACC/AHA/ESC Guidelines: Warfarin vs Aspirin

48. Warfarin: The Gold Standard

49. Currently Available Oral Anticoagulants

50. Clinical Trial Data

51. Limitations/Concerns With Available Anticoagulants

52. Visit TEAManticoag.com for a Medication Chart (Keyword: chart)

53. ACC/AHA/ESC Guidelines: Managing Through Medical Procedures to Prevent Thrombosis

54. Drug-Specific Guidelines for Managing Through Medical Procedures

55. When to Switch From Warfarin

56. Remain With Warfarin if …

57. Switching From Warfarin: How?

58. Visit TEAManticoag.com for Tools, Handouts, Calculators, and More

59. Periprocedural Anticoagulation Algorithm on TEAManticoag.com (Keyword: periprocedural)

60. Decision Tool to Use With Patients on TEAManticoag.com (Keyword: decision)

61. TEAM-A Town Hall on TEAManticoag.com